CLINICAL TRIALS PROFILE FOR SUMATRIPTAN AND NAPROXEN SODIUM
✉ Email this page to a colleague
All Clinical Trials for Sumatriptan And Naproxen Sodium
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00240617 ↗ | Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks | Completed | GlaxoSmithKline | Phase 3 | 2005-10-01 | The purpose of this study is to determine the consistency of response for Treximet (formerly known as Trexima) when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain. |
NCT00240630 ↗ | Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks | Completed | GlaxoSmithKline | Phase 3 | 2005-10-01 | The purpose of this study is to determine the consistency of response for Treximet (sumatriptan/naproxen sodium), formerly known as Trexima, when treating four acute migraine attacks at the mild pain phase and within 1 hour of onset of head pain. |
NCT00329355 ↗ | Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA) | Completed | GlaxoSmithKline | Phase 3 | 2006-05-01 | This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine. |
NCT00329459 ↗ | Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea | Completed | GlaxoSmithKline | Phase 3 | 2006-05-01 | This study was designed to determine efficacy of TREXIMA compared to placebo for the treatment of a menstrual migraine. |
NCT00382993 ↗ | A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) | Completed | GlaxoSmithKline | Phase 3 | 2006-12-01 | This is a randomized, double-blind, placebo-controlled, crossover, two-attack, out-patient, early-intervention evaluation of subjects who have migraine with or without aura and who discontinued use of short acting triptan(s) within the past year due to non-response or intolerance. Subjects will treat 2 separate migraine attacks during the mild phase of each attack; one attack will be treated with one tablet of the Combination Product (sumatriptan succinate and naproxen sodium) and the other attack with one tablet of placebo (crossover design). [Study 2 of 2] |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Sumatriptan And Naproxen Sodium
Condition Name
Clinical Trial Locations for Sumatriptan And Naproxen Sodium
Trials by Country
Clinical Trial Progress for Sumatriptan And Naproxen Sodium
Clinical Trial Phase
Clinical Trial Sponsors for Sumatriptan And Naproxen Sodium
Sponsor Name